Serum α-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma

Oncologist

Volumn 14, Issue 7, 2009, Pages 717-725

  Vora, Sadhna R ^a   Hui, Zheng ^a   Stadler, Zsofia K ^a   Fuchs, Charles S ^a   Zhu, Andrew X ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

fetoprotein; Carcinoma; Clinical trial; Drug response biomarkers; Hepatocellular

Indexed keywords

ALPHA FETOPROTEIN; BEVACIZUMAB; CETUXIMAB; EPIRUBICIN; GEMCITABINE; OXALIPLATIN; SUNITINIB; THALIDOMIDE;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANK SUM TEST; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 68449100731     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0038     Document Type: Article

References (38)

1. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002.CA Cancer J Clin 2005;55:74-108.
2. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37(suppl 8):S4-S66. (Pubitemid 32973189)
3. El-Serag HB, Davila JA, Petersen NJ et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: An update. Ann Intern Med 2003;139:817-823.
4. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750. (Pubitemid 29114292)
5. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
6. World Health Organization. Reporting of Response: WHO Handbook for Reporting Results of Cancer Treatment. Geneva: WHO, 1979:335.
7. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-216.
8. Leung TW, Patt YZ, Lau WY et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999;5:1676-1681.
9. Nauta RJ, Heres EK, Thomas DS et al. Intraoperative single-dose radiotherapy. Observations on staging and interstitial treatment of unresectable liver metastases. Arch Surg 1987;122:1392-1395.
10. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24: 4293-4300. (Pubitemid 46630787)
11. Aoyagi Y, Suzuki Y, Igarashi K et al. Carbohydrate structures of human alpha-fetoprotein of patients with hepatocellular carcinoma: Presence of fucosylated and non-fucosylated triantennary glycans. Br J Cancer 1993; 67:486-492. (Pubitemid 23077641)
12. Nomura F, Ohnishi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer 1989;64:1700-1707. (Pubitemid 19251142)
13. Izumi R, Shimizu K, Kiriyama M et al. Alpha-fetoprotein production by hepatocellular carcinoma is prognostic of poor patient survival. J Surg Oncol 1992;49:151-155.
14. Stillwagon GB, Order SE, Guse C et al. Prognostic factors in unresectable hepatocellular cancer: Radiation Therapy Oncology Group study 83-01. Int J Radiat Oncol Biol Phys 1991;20:65-71.
15. Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 1996; 77:2217-2222.
16. Trevisani F, D'Intino PE, Morselli-Labate AM et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: Influence of HBsAg and anti-HCV status. J Hepatol 2001;34:570-575. (Pubitemid 32328514)
17. Farinati F, Marino D, De GiorgioMet al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: Both or neither? Am J Gastroenterol 2006;101:524-532. (Pubitemid 43340928)
18. Matsumoto Y, Suzuki T, Ono H et al. Evaluation of hepatoma chemotherapy by alpha-fetoprotein determination. Am J Surg 1976;132:325-328.
19. Choi TK, Lee NW, Wong J. Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy. Cancer 1984;53: 401-405.
20. Chen LT, Liu TW, Chao Y et al. Alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma. Aliment Pharmacol Ther 2005;22:217-226. (Pubitemid 41153064)
21. Chan SL, Mo FK, Johnson PJ et al. New utility of an old marker: Serial α-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 2009;27:446-452.
22. Fuchs CS, Clark JW, Ryan DP et al. A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2002;94:3186-3191. (Pubitemid 34670502)
23. Zhu AX, Fuchs CS, Clark JW et al. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. The Oncologist 2005;10:392-398. (Pubitemid 40993567)
24. Zhu AX, Blaszkowsky LS, Ryan DP et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:1898-1903. (Pubitemid 46638989)
25. Zhu AX, Stuart K, Blaszkowsky LS et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007;110:581-589.
26. Zhu AX, Sahani DV, Duda DG et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study. J Clin Oncol 2009;27:3027-3035.
27. Sugawara K, Kashii A, Kogure H et al. Serum alpha-fetoprotein and resection in primary hepatic cancer. Arch Surg 1973;106:63-65.
28. Thomas MB, Chadha R, Glover K et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007;110:1059-1067. (Pubitemid 47312872)
29. Plunkett W, Huang P, Searcy CE et al. Gemcitabine: Preclinical pharmacology and mechanisms of action. Semin Oncol 1996;23(suppl 10):3-15. (Pubitemid 26362189)
30. D'Amato RJ, Loughnan MS, Flynn E et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994;91:4082-4085.
31. Louvet C, André T, Lledo G et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: Final results of a GERCOR multicenter phase II study. J Clin Oncol 2002;20:1512-1518. (Pubitemid 34260530)
32. Goldstein NI, Prewett M, Zuklys K et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995;1:1311-1318.
33. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005;315:971-979. (Pubitemid 41635382)
34. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-337.
35. Pawson T. Regulation and targets of receptor tyrosine kinases. Eur J Cancer 2002;38(suppl 5):S3-S10.
36. Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 2001;5:145-159. (Pubitemid 32118643)
37. Collier J, Sherman M. Elevated alphafetoprotein in benign liver diseases. Viral Hepatitis Rev 1998;4:31.
38. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998;27:273-278.